The inquiry showed that originator companies use a variety of instruments to extend the commercial life of their products without generic entry for as long as possible.
Uuringust nähtus, et originaalravimite tootjad kasutavad oma toodete kaubanduslikult kasuliku eluea pikendamiseks ja geneeriliste ravimite turuletuleku pidurdamiseks mitmesuguseid strateegiaid.